Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…Abstract Number: 67 • 2019 ACR/ARP Annual Meeting
Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model
Background/Purpose: Lymphatic vessels are important in limiting the extent and duration of peripheral immune response, both by transporting cellular debris, inflammatory cells and excess interstitial…Abstract Number: 637 • 2019 ACR/ARP Annual Meeting
How Often Should SLE Patients Be Tested for Lupus Anticoagulant?
Background/Purpose: SLE patients with persistent lupus anticoagulant (LAC) have been observed to be at significantly higher risk of thrombosis. A common clinical definition of persistent…Abstract Number: 686 • 2019 ACR/ARP Annual Meeting
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
Background/Purpose: There is a lack of reliable biomarkers for disease activity in SLE. While C3a, an anaphylatoxin generated during of complement activation, could be predictive…Abstract Number: 952 • 2019 ACR/ARP Annual Meeting
Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population
Background/Purpose: Medicare measures readmissions within 30 days of hospitalization across several conditions as a marker of care quality. While not currently a reporting condition, in…Abstract Number: 1105 • 2019 ACR/ARP Annual Meeting
Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus
Background/Purpose: At present, there are few researches on cognitive emotional regulation, body image, family and marital function, and life quality of female patients with systemic…Abstract Number: 1570 • 2019 ACR/ARP Annual Meeting
Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
Background/Purpose: : In a related study, we have shown evidence to support the validity of the Automated Neuropsychological Assessment Metrics (ANAM) for the screening of…Abstract Number: 1615 • 2019 ACR/ARP Annual Meeting
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Background/Purpose: Autoantibodies against N-methyl-D-aspartate receptor subunit GluN2 (anti-GluN2) in the cerebrospinal fluid are known to be related with the development of diffuse psychiatric/neuropsychological manifestations in…Abstract Number: 1825 • 2019 ACR/ARP Annual Meeting
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Background/Purpose: We previously developed a Thrombosis Risk Score, a sum of three factors: lupus anticoagulant (by RVVT confirm); low C3; and C4d bound to platelets.…Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…Abstract Number: 2518 • 2019 ACR/ARP Annual Meeting
Time to Lupus Low Disease Activity State: Role of African-American Ethnicity
Background/Purpose: Lupus Low Disease Activity State (LLDAS) is a potential treat to target goal in systemic lupus erythematosus (SLE). It is well established that SLE…Abstract Number: 2553 • 2019 ACR/ARP Annual Meeting
Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Background/Purpose: We recently reported prescription opioid use in nearly one-third of systemic lupus erythematosus (SLE) patients in our population-based cohort. Data suggest that opioids may…Abstract Number: 2781 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk for cardiovascular disease (CVD). SLE itself predisposes patients to accelerated atherosclerosis. In addition, the…Abstract Number: 68 • 2019 ACR/ARP Annual Meeting
Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus
Background/Purpose: Deficiency of transaldolase (TAL) in systemic lupus erythematosus (SLE) predisposes to oxidative stress mediated autoimmune hepatitis[1, 2]. Along with TAL, HRES-1/Rab4 (Rab4A), a small…Abstract Number: 638 • 2019 ACR/ARP Annual Meeting
Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus
Background/Purpose: To characterize the longitudinal trajectory of estimated glomerular filtration rate (eGFR) in patients with systemic lupus erythematosus (SLE) and identify predictors of change in…
- « Previous Page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- …
- 150
- Next Page »